You'll see fewer patients getting prescriptions for the antidepressant Serzone

February 2003

You'll see fewer patients getting prescriptions for the antidepressant Serzone...due to concerns about liver toxicity.

Bristol-Myers Squibb just pulled it off the market in Europe.

The FDA added a black box warning last year.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote